

Analgesics in Norway

Market Direction | 2022-10-07 | 26 pages | Euromonitor

AVAILABLE LICENSES:

- Single User Licence €825.00
- Multiple User License (1 Site) €1650.00
- Multiple User License (Global) €2475.00

Report description:

Following strong growth in 2021 due to consumers stockpiling analgesics to manage COVID-19 symptoms, the category is expected to see its sales growth strongly decelerate in 2022. This is because the COVID-19 virus is no longer a severe threat to the Norwegian population given the success of the vaccination programme and the general subsiding of the pandemic. As such, consumption and demand for analgesics is starting to normalise for most people. Adult acetaminophen was particularly sought-after...

Euromonitor International's Analgesics in Norway report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2017-2021, allowing you to identify the sectors driving growth. Forecasts to 2026 illustrate how the market is set to change.

Product coverage: Systemic Analgesics, Topical Analgesics/Anaesthetic.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?

- * Get a detailed picture of the Analgesics market;
- * Pinpoint growth sectors and identify factors driving change;
- * Understand the competitive environment, the market's major players and leading brands;
- * Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.

Table of Contents:

Analgesics in Norway Euromonitor International October 2022

List Of Contents And Tables

ANALGESICS IN NORWAY

KEY DATA FINDINGS

2022 DEVELOPMENTS

Fewer COVID-19 cases and the vaccination roll-out limit demand for analgesics

E-commerce returns to moderate growth as consumers adopt old shopping habits

Switch to Rx removes adult diclofenac from retail sales landscape

PROSPECTS AND OPPORTUNITIES

Return to normal life expected to drive steady growth in analgesics

Growth may be limited by consumers taking a more natural approach to their health and wellbeing

Dominance for top brands to continue thanks to strong consumer loyalty

CATEGORY DATA

Table 1 Sales of Analgesics by Category: Value 2017-2022

Table 2 Sales of Analgesics by Category: % Value Growth 2017-2022

Table 3 NBO Company Shares of Analgesics: % Value 2018-2022

Table 4 LBN Brand Shares of Analgesics: % Value 2019-2022

Table 5 Forecast Sales of Analgesics by Category: Value 2022-2027

Table 6 Forecast Sales of Analgesics by Category: % Value Growth 2022-2027

CONSUMER HEALTH IN NORWAY

EXECUTIVE SUMMARY

Consumer health in 2022: The big picture

2022 key trends

Competitive landscape

Retailing developments

What next for consumer health?

MARKET INDICATORS

Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2017-2022

Table 8 Life Expectancy at Birth 2017-2022

MARKET DATA

Table 9 Sales of Consumer Health by Category: Value 2017-2022

Table 10 Sales of Consumer Health by Category: % Value Growth 2017-2022

Table 11 NBO Company Shares of Consumer Health: % Value 2018-2022

Table 12 LBN Brand Shares of Consumer Health: % Value 2019-2022

Table 13 Penetration of Private Label in Consumer Health by Category: % Value 2017-2022

Table 14 Distribution of Consumer Health by Format: % Value 2017-2022

Table 15 Distribution of Consumer Health by Format and Category: % Value 2022

Table 16 [Forecast Sales of Consumer Health by Category: Value 2022-2027

Table 17 [Forecast Sales of Consumer Health by Category: % Value Growth 2022-2027

APPENDIX

OTC registration and classification

Vitamins and dietary supplements registration and classification

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Self-medication/self-care and preventive medicine

Switches

Summary 1 OTC: Switches 2021-2022

DISCLAIMER
DEFINITIONS
SOURCES

Summary 2 Research Sources

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com



☐ - Print this form

To place an Order with Scotts International:

 $\hfill \Box$ - Complete the relevant blank fields and sign

Analgesics in Norway

Market Direction | 2022-10-07 | 26 pages | Euromonitor

Select license	License				Price
	Single User Licence				€825.00
	Multiple User License (1 Site)				€1650.00
	Multiple User License (Global)				€2475.00
				VAT	
				Total	
mail*				unable to provide a	
:mail*		Phone*	Lipanies wild are c	anuble to provide u	
				anuble to provide u	
First Name*		Phone*		anuble to provide u	Vulla Eo V
First Name* ob title*		Phone*		anubic to provide u	
Email* First Name* ob title* Company Name* Address*		Phone* Last Name*			
First Name* ob title* Company Name*		Phone* Last Name* EU Vat / Tax ID / N			
First Name* ob title* Company Name* Address*		Phone* Last Name* EU Vat / Tax ID / N City*			

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com